19 September 2021
By Max Holloway

LYPHE Group, Europe’s first Medical Cannabis multi-national operator launches Swiss Operations

Lyphe Group

MEDCAN Praxis, a medical cannabis patient access platform wholly owned by LYPHE, will begin enabling patient access to specialist doctors across Switzerland from today.

The move comes as Dr Reto Agosti joins LYPHE as Chief Medical Officer, Switzerland, with the remit of clinical oversight across the Swiss medical cannabis ecosystem. Dr Agosti is a prominent headache expert and Neurologist, having spent his career at University Hospital Zurich, and Harvard Medical Centres, Boston, USA before founding Switzerland’s leading headache centre, Kopfwehzentrum Hirslanden. 

LYPHE has created the blueprint for capturing medical cannabis markets across Europe, dispensing to more than 60% of all patients in the UK using its clinical care platform and pharmacy services.

It is expected that the number of Swiss patients receiving medical cannabis treatment will go up to 100,000 per year by 2023. The impending change in Swiss law to remove the ‘exceptional authorisation’ and therefore allow doctors and their patients a simpler and quicker route to access medical cannabis will be an important catalyst for this growth.

LYPHE CEO and Co-founder, Dean Friday, said of the new venture in Switzerland: “The Swiss market is a hugely exciting market. We wanted to enter early in the same way we entered the UK – where we hold a dominant market position. 

Every new market comes with its own unique set of challenges, and our team has navigated them successfully to create an ecosystem that will dominate across the vertical from import, processing and dispensing direct to patient. Today we begin facilitating patient-care in partnership with Dr Agosti, one of the most highly regarded neurologists in Switzerland.” 

LYPHE’s newly appointed Chief Medical Officer, Switzerland, Dr Reto Agosti added, “I am delighted to be joining LYPHE. I was very happy to see their patient focused approach in widening access to medical cannabis.

LYPHE will be facilitating the market’s growth through patient and doctor education, expanding product availability, alongside specialist clinical care and dispensing services. MEDCAN Praxis is a great concept and will be appreciated by Swiss patients.”

Over the coming months, LYPHE will launch the other elements of its Swiss ecosystem – ensuring patients receive their treatment on time, to their door. Switzerland will be quickly followed by launches into other European medical markets over the coming months.